Member Info for Tp23

Allan, thank you for your post, personally I believe if the company have been able to communicate with yourself that "all is back on track" then why couldn't they communicate that formally with all their shareholders? People have made financial decisions on statements made by the company, statements which at the least could be regarded as questionable? and now, shareholders deserve better communication certainly if confidence in this BOD is to be regained?

JB - Lack of transparency? That’s an understatement!
12/3/18 RNS - “commenced mobilisation of the Jack up rig for delivery direct to Nigeria” “COSL Force is a ‘hot rig’ (tooled up and ready to operate”?!?!?! Bobo Kuti “excellent work they have done on mobilisation”????
1/5/18 RNS - “the company expects to be able to provide an update on timing for the spudding of the Ororo-2 well in the Near Term”?
7/6/18 RNS - COSL commences critical equipment re-certification? So much for it being a ‘hot rig tooled up and ready to operate’ and Bobo Kuti announces “pleased to be back on track”?? Back on track? the licence runs out next May!
To date I have not had one response from any email sent to the company despite the company website stating “The Group values the views of its shareholders and recognises their interest in the Groups strategy and performance”.

Reggie, one of the questions I have been seeking an answer from the company is in relation to the OML 95 licence which was previously extended by the Nigerian Govt on 1st May 2016 for 3 years so, I hope the spud is not delayed until Q2 next year or I presume they will need to apply for another extension?

Has anyone managed to email the company with a question and receive a response?? I’ve emailed the company twice with questions and both times failed to obtain a reply??

http://petrobarometer.thecable.ng/2018/08/28/exclusive-buhari-rejects-pigb-says-it-whittles-down-his-power/

Hope this does not add to the delays?

New-2, many thanks.

Guys a question to the experienced, is it correct that if the company is taken over then an offer has to be made greater than the highest share price over the previous 12 months?

COSLPower in Nigeria? https://www.infield.com/rigs/coslpower-jackup-60655.

Sept 13 (Reuters) - A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over. Panel members said they were "very impressed" by efficacy data from Shingrix clinical trials, and that it represents an improvement over Zostavax, the only marketed shingles prevention vaccine from Merck & Co. While the FDA is not required to follow recommendations of its advisory panels, the enthusiasm expressed would seem to indicate that approval is a virtual certainty in coming weeks. Shingrix is considered one of the more important products in GSK's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data.